Fintech PR
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
HERZLIYA, Israel and CALGARY, Alberta, April 1, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023.
Full Year 2023 Financial Highlights
- Revenues increased 534% year-over-year to US$13.7 million, compared to US$2.6 million in 2022. This significant increase in revenue was primarily due to the robust sales performance of Innocan’s subsidiary, BI Sky Global Ltd.
- Gross Profit increased 568% year-over-year to US$12.0 million for the year ended December 31, 2023, compared to US$2.1 million for 2022.
- Operating loss decreased by 61% to US$3.8 million in 2023, compared to US$6.3 in 2022.
- The Company completed a $1.5 million capital raise in March 2024.
Management Comments
Iris Bincovich, the CEO of Innocan commented: “We are very pleased with our performance in 2023, closing the year with a strong fourth quarter. This was due to the strong execution by our team in the quarter as well as throughout the year. We delivered impactful, customer-centric innovation and thoughtfully managed all aspects of our operation. Our accomplishments during the year as well as our progress on executing on our strategy has enabled us to exceed our financial targets for 2023.”
“We are pursuing FDA approval of our LPT CBD-loaded liposome platform which facilitates exact dosing and controlled release of CBD into the blood stream for use by patients who suffer from Chronic pain.” continued Ms. Bincovich. “We remain committed to our vision. It is definitely an exciting time for Innocan Pharma and our shareholders.”
Roni Kamhi, CEO BI Sky Global and COO of Innocan Pharma commented: “Our consumer wellness products are trusted by millions of customers. We at BI Sky Global are very pleased with the results of 2023. We have leveraged our deep understanding of the cosmetics space together with our know-how in leveraging data and analytics to identify and best service our customers. We also look forward to further strengthening BI Sky Global as a leader in the beauty and personal care products space.”
For further details of Innocan’s audited consolidated financial statements and related management’s discussion and analysis for the year ended December 31, 2023, please visit the Company’s profile at www.sedar.com.
About Innocan
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Pain Management and Epilepsy. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti-inflammatory properties targeting the central nervous system. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary note regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-full-year-2023-results-with-revenues-up-nearly-6x-to-13-7m-302104639.html
The promotions span across six practice areas and three regions to drive growth in 2025 and beyond
CHICAGO, Jan. 6, 2025 /PRNewswire/ — Heidrick & Struggles (Nasdaq: HSII), a premier provider of global leadership advisory and on-demand talent solutions, today announced key global and regional leader appointments, effective January 1, 2025. The appointed leaders will continue advancing the firm’s objective of delivering exceptional value to clients by fostering differentiated, deep, and durable relationships.
“Having the right leadership in place is increasingly crucial to business performance, growth, and prosperity, making our work more important than ever,” said Tom Monahan, CEO, Heidrick & Struggles. “This dynamic group embodies our values as a firm as well as our unwavering commitment to delivering superior client service. We’re excited to promote these outstanding leaders as they continue to shepherd our clients through their most pressing business and talent challenges.”
These leaders span Heidrick & Struggles’ priority practice and solution areas, as well as multiple regions globally.
Individuals appointed to Regional Leader:
- Anne Rockey, North America
- Richard Guest, Asia Pacific & Middle East
Individual appointed to Global Managing Partner:
- Todd Taylor, Client Driven Growth, a newly created role
Individuals appointed to Executive Search Global Practice Managing Partner:
- Jaimee Eddington, Corporate Officers Practice
- Dominique Fortier, Financial Services Practice
- Chris Bray, Global Technology & Services Practice
- Gustavo Alba, Co-Lead, Private Equity Practice
Individuals appointed to Executive Search Regional Practice Managing Partner:
- Liz Langel, Americas, Financial Services Practice
- Ina Sood, Americas, Healthcare & Life Sciences Practice
- David Burd, Americas, Corporate Officers Practice
- David Crawford, Asia Pacific & Middle East, Global Technology & Services Practice
- Tom Cunningham, Europe & Africa, Global Technology & Services Practice
- Sarah Driscoll, Europe & Africa, Global Technology & Services Practice
- Roman Wecker, Europe & Africa, Industrial Practice
Individuals appointed to Partner-in-Charge:
- Jane Xing, Beijing
- Jessi Gentile, Chicago
- Maliha Jilani, Dubai
- Kim Pomoell, Finland
- Kiwook Kim, Korea
- David Richardson, New York/Stamford
- Christina Besozzi Cary, Washington, D.C.
Individual promoted in Heidrick Consulting:
- Eric Joseph, leading North America on an interim basis
About Heidrick & Struggles
Heidrick & Struggles (Nasdaq: HSII) is a premier provider of global leadership advisory services and on-demand talent solutions, serving the senior talent and consulting needs of the world’s top organizations. Heidrick & Struggles pioneered the profession of executive search more than 70 years ago. Today, we partner with clients to develop future-ready leaders and organizations, combining our expertise in executive search, leadership consulting, and on-demand, critical talent solutions to achieve the highest levels of profitability and performance. Helping our clients change the world, one leadership team at a time.® www.heidrick.com
Media Contact
Bianca Wilson
Global Director, Public Relations
Heidrick & Struggles
[email protected]
Logo – https://mma.prnewswire.com/media/139029/heidrick_struggles_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/heidrick–struggles-announces-2025-global-and-regional-leader-appointments-302343456.html
LONDON, Jan. 6, 2025 /PRNewswire/ — Finastra, a global provider of financial services software applications, today announced a significant leadership transition. After nearly a decade of transformative leadership, Simon Paris will step down from his role as Chief Executive Officer. Chris Walters has joined Finastra and will assume the role of Chief Executive Officer.
Chris brings a wealth of experience from senior executive leadership positions, driving innovation and scaling technology companies. He recently served as CEO of Pluralsight and Avantax, a leading company within Financial Services, where he orchestrated significant performance improvement and the company’s successful sale. Prior to Pluralsight and Avantax, Chris served in a variety of leadership roles, including being a Partner at McKinsey & Company and the COO of Bloomberg Industry Verticals Group.
On his appointment, Chris said, “I’m excited to join Finastra at this pivotal moment in its journey and am impressed by the significant progress that has been made during Simon’s leadership. I look forward to working with the talented team to drive sustainable growth and continue to deliver more value to our customers, team members, and investors.”
Under Simon’s stewardship, the company has achieved remarkable milestones, including:
- Leading the charge in Open Finance, following the merger of Misys and D+H in 2017 to form Finastra
- Building a loyal customer base of over 8,000 clients in 130 countries, including 45 of the world’s top 50 banks
- Achieving recognition as a leader in Generative AI, with all employees upskilled and ~50 capabilities in progress from ideation to production stages
- Garnering extensive market accolades, including multiple product, culture, and leadership awards, and being named the #1 Banking Technology company, the #2 Financial Technology company, and appearing in the top 15 Software companies worldwide in 2024 alone
- Delivering record financial performance and double-digit Annual Recurring Revenue (ARR) growth
As Finastra embarks on its new strategic sprint in 2025, the company is well-positioned for continued success. During the transition period, Simon and Chris will work closely together to ensure a smooth handover.
Simon reflected on his tenure, saying, “This journey with Finastra has been a privilege. Chris is a seasoned professional, and I am honored to ‘pass the baton’ to him. I leave incredibly proud of what Finastra has achieved so far and excited for the company’s future under Chris’s leadership.”
About Finastra
Finastra is a global provider of financial services software applications across Lending, Payments, Treasury and Capital Markets, and Universal (retail and digital) Banking. Committed to unlocking the potential of people, businesses and communities everywhere, its vision is to accelerate the future of Open Finance through technology and collaboration, and its pioneering approach is why it is trusted by ~8,100 financial institutions, including 45 of the world’s top 50 banks. For more information, visit finastra.com.
Photo – https://mma.prnewswire.com/media/2591526/Simon_Paris_and_Chris_Walters.jpg
Logo – https://mma.prnewswire.com/media/1916021/5100855/FINASTRA_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/finastra-announces-leadership-transition-welcoming-chris-walters-as-new-ceo-302343232.html
AI Impact leverages DXC’s combined consulting, engineering, and secure enterprise services
ASHBURN, Va., Jan. 6, 2025 /PRNewswire/ — DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced AI Impact, an approach designed to help solve customers’ most pressing challenges. By combining DXC consulting, engineering and secure enterprise services, DXC will help clients across industries securely innovate and drive real business outcomes with AI.
DXC takes a pragmatic approach to AI by focusing on developing solutions that solve real world challenges and support business growth. With DXC’s AI Impact, customers benefit from DXC’s vast industry expertise and technology experience to build solutions, services and experiences together that will deliver real business outcomes using the latest technology innovation. Read more about DXC’s approach here.
“AI has already captured the attention and imagination of industries everywhere. From AI agents to autonomous driving and personalized medicine, companies are taking steps to unlock value from AI, which promises to reshape our world,” said Howard Boville, EVP, Consulting & Engineering Services – Powered by AI. “With DXC’s AI Impact approach, we are helping to push the boundaries of what AI makes possible, guided by our team of consulting, engineering and technology experts to address our clients’ most pressing challenges.”
Customers across industries are leveraging AI Impact, including:
- Automotive: DXC is helping customers leverage AI-powered diagnostic tools to make it easier for automotive manufacturers and service providers to identify potential issues before they become critical, reducing downtime and maintenance costs. DXC is also helping customers leverage AI to personalize every aspect of a vehicle, including personal assistants that learn a driver’s preferences and habits over time to make more intuitive recommendations.
- Public Sector: To provide more transparency, governments are using DXC AI Impact to efficiently engage with citizens and make it easier for them to access public services. This includes the use of AI Agents and AI enhanced processes that streamline and simplify tax, national lending and even public healthcare processes.
- Financial Services and Insurance: DXC is helping customers optimize operations, from underwriting and risk assessment to claims processing and customer service. By working with DXC, financial institutions are leveraging chatbots to make it easy for human agents to respond faster and more accurately to customer inquiries by analyzing thousands of documents in minutes with Generative AI.
- Healthcare: DXC implemented an AI-powered app to help measure patient symptoms in real-time, analyzing data to provide clinicians with insights that enable more accurate diagnoses and treatment plans, improving the quality of care and proactively addressing prescription resistance.
For more information on DXC AI Impact and how we’re working with the most innovative industry leaders to securely innovate, visit here.
Forward Looking Statements
All statements in this press release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” These statements represent current expectations and beliefs, and no assurance can be given that any result, goal or plan set forth in any forward-looking statement can or will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. For a written description of these factors, see the section titled “Risk Factors” in DXC’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, and any updating information in subsequent SEC filings. Readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, except as required by law.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.
CONTACT: Mihir Bellamkonda, Media Relations, [email protected]; Roger Sachs, Investor Relations, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/dxc-technologys-ai-impact-helps-customers-across-industries-innovate-with-ai-302343102.html
-
Fintech PR7 days agoOutsourced Accounting Service: The New Standard for Business Finance Industry
-
Fintech PR7 days agoBybit Launchpad Onboards Xterio, Opening up Opportunities in Blockchain Gaming for Users
-
Fintech PR6 days agoCKGSB Professor Mei Jianping Launches Global Indices Tracking Impressionist, Contemporary, and Chinese Art Markets
-
Fintech PR7 days agoIBN Technologies Sets the Benchmark in Financial Management Accounting Excellence
-
Fintech PR3 days agoBybit x Block Scholes Report: BTC Options Steady with Call-Put Parity, ETH Braces for Short-Term Volatility
-
Fintech PR6 days agoDayOne Launches as an Independent Global Data Center Pioneer Following Series B Funding Closure
-
Fintech PR6 days agoGES Completes Sale to Truelink Capital
-
Fintech PR3 days agoArtificial Intelligence (AI) in Trading Market to Reach USD 35 Billion by 2030, Growing at a 10% CAGR | Valuates Reports